{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.49","value":"2.9"},{"groupId":"OG001","spread":"20.55","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"249"},{"groupId":"OG001","value":"118"}],"units":"Participants"}],"title":"Cycle 1 Day 1 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.95","value":"-3.1"},{"groupId":"OG001","spread":"20.11","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"142"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"Cycle 1 Day 1 - 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.95","value":"-2.0"},{"groupId":"OG001","spread":"20.11","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"122"}],"units":"Participants"}],"title":"Cycle 1 Day 1 - 2 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.47","value":"-0.9"},{"groupId":"OG001","spread":"19.75","value":"3.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"68"}],"units":"Participants"}],"title":"Cycle 1 Day 1 - 3 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.47","value":"-1.9"},{"groupId":"OG001","spread":"20.11","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"Cycle 1 Day 1 - 4 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.99","value":"3.9"},{"groupId":"OG001","spread":"50.43","value":"5.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"91"}],"units":"Participants"}],"title":"Cycle 1 Day 21 - Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.60","value":"-1.3"},{"groupId":"OG001","spread":"20.48","value":"0.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"177"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"title":"Cycle 1 Day 21 - 1 hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.28","value":"1.6"},{"groupId":"OG001","spread":"19.57","value":"4.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"212"},{"groupId":"OG001","value":"117"}],"units":"Participants"}],"title":"Cycle 1 Day 21 - 2 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.41","value":"1.2"},{"groupId":"OG001","spread":"18.29","value":"2.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"59"}],"units":"Participants"}],"title":"Cycle 1 Day 21 - 3 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.91","value":"0.2"},{"groupId":"OG001","spread":"20.13","value":"2.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"56"}],"units":"Participants"}],"title":"Cycle 1 Day 21 - 4 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.61","value":"1.7"},{"groupId":"OG001","spread":"24.96","value":"5.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"213"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"title":"Cycle 2 Day 21 - 2 hours"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"72.35","value":"4.2"},{"groupId":"OG001","spread":"22.06","value":"1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"132"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Cycle 3 Day 21 - 2 hours"}],"denoms":[{"counts":[{"groupId":"OG000","value":"258"},{"groupId":"OG001","value":"122"}],"units":"Participants"}],"description":"QT Interval: Ventricular depolarization plus ventricular repolarization Normal Range: 400 to 460 msec. QTc: QT interval corrected based on the patient's heart rate. QTcB: An electrocardiographic finding in which the QT interval corrected for heart rate using Bazzett's formula.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received 5 mg of fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG000","title":"Fruquintinib + BSC Group"},{"description":"Participants received placebo matched to fruquintinib oral capsule in combination with BSC once daily for 3 weeks of continuous dosing followed by a 1-week break during a treatment cycle (Each cycle length was 28 days).","id":"OG001","title":"Placebo + BSC Group"}],"paramType":"MEAN","populationDescription":"SP included all randomized participants who received at least 1 dose of study drug. Here, \"Overall Number of Participants Analyzed\" signifies those participants who were evaluable for this outcome measure and \"Number analyzed\" signifies those participants who were evaluable at the specified timepoints.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 1 (Day 1 and 21): Pre-dose, 1, 2, 3 and 4 hours; Cycle 2 and 3 (Day 21): Pre-dose (Each cycle = 28 days)","title":"Change From Baseline of ECG Results -QTcB Intervals Using Bazzett's Formula","type":"SECONDARY","unitOfMeasure":"msec"}